The company’s reduction in workforce comes as it continues to focus on implementing “innovative” manufacturing technologies to better produce novel drugs.
The company is adding to a biologics manufacturing site in Frederick and building a facility in Gaithersburg for the development and supply of drugs for clinical trials.
This week, the industry saw a flurry of pharma manufacturing investment announcements as companies continue to onshore production in the United States.
The Swiss pharma giant intends to nearly double its operational footprint in the state to more than 700,000 square feet between the existing campus and new facilities.
The tariff rate on pharmaceuticals imported from Switzerland and Liechtenstein to the United States is in line with Trump’s trade agreement in late July with the EU.
The adoption of artificial intelligence has evolved with investment shifting from monitoring to predictive intelligence, according to the 2025 LogiPharma AI Report.
Eli Lilly and Novo Nordisk are latest to accept quid pro quo of Most Favored Nation drug pricing and onshoring of pharmaceutical manufacturing for tariff exemptions.
The CDMO, which specializes in sterile injectables, is investing in a dual-continent expansion strategy at its sites in Bloomington, Indiana and Halle/Westfalen, Germany.
Raleigh-Cary and Durham-Chapel Hill secured the first and third spots, respectively, as the nation’s most competitive markets for the production of therapeutic biologics.
While Big Pharma has the resources to invest in domestic production, smaller biotech companies increasingly rely on contract manufacturers who need help.
SymphonX, which runs all downstream unit operations in both fed-batch and continuous processes, will serve customers at Fujifilm’s Billingham manufacturing facility.
With $1.3 billion in funding, the company has established a cGMP manufacturing facility in Waltham, Massachusetts, with a second site under construction in Pittsburgh.
After attending last week’s CPHI Frankfurt conference, William Blair analysts contend that contract development and manufacturing organizations are poised to grow next year.
This year’s Pharma Innovation Awards recognize those products and services advancing pharmaceutical manufacturing with new approaches and technologies.
U.S. CDMOs with commercial manufacturing assets are likely to reach above market growth, according to Brian Scanlan, advisor of life sciences at Edgewater Capital Partners.
Cytiva’s 2025 Global Biopharma Index shows widening gaps across regions as talent shortages, regulatory strain, and uneven sustainability progress weigh on growth.
The company reported strong demand for bioconjugates, mammalian, and small molecules, with no material financial impact expected from current U.S. trade policies.
Marc Casper contends Thermo Fisher’s pharma and biotech customers will be able to navigate the Trump administration’s MFN drug pricing framework and tariffs.
The CDMO has expanded production at its Bioconjugation Center of Excellence in St. Louis and partnered with Simtra to better serve the growing antibody-drug conjugate market.
While the plant was recently hit with the FDA’s most severe post-inspection classification, it is a facility that has been plagued with problems for several years.
An AI-powered platform creates a digital replica of manufacturing sites, helping companies improve efficiency, reduce downtime, and prepare for supply chain disruptions.